# NAD Supplementation in Parkinson's Disease

> **NCT07703137** · NA · ENROLLING_BY_INVITATION · sponsor: **University of Oklahoma** · enrollment: 40 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DIETARY_SUPPLEMENT:** Nicotinamide Riboside (NR)
- **DIETARY_SUPPLEMENT:** Oral placebo capsules

## Key facts

- **NCT ID:** NCT07703137
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-08-10
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703137, "NAD Supplementation in Parkinson's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*